Key highlights
- Confirmed 69% objective response rate in patients with KRAS G12D or G12V pancreatic cancer
- Reported 60% confirmed objective response rate in KRAS-mutant non-small cell lung cancer at 32 mg QD
- Accelerated initiation of Phase 3 trial in first-line pancreatic cancer to H1 2027
- Maintained 100% median relative dose intensity at the 32 mg pharmacologically active dose
- Initial data for pan-KRAS inhibitor ERAS-4001 supports potential combination therapy with ERAS-0015
Phase 1 Clinical Results
Erasca disclosed updated interim results from its AURORAS-1 Phase 1 trial evaluating ERAS-0015, a pan-RAS molecular glue. In patients with KRAS G12D or G12V mutant pancreatic ductal adenocarcinoma treated at 32 mg once daily, the drug achieved a 69% confirmed objective response rate. Among the 13 patients in this subset, 77% had previously received at least three lines of therapy. Furthermore, the monotherapy showed a 60% objective response rate in KRAS-mutant non-small cell lung cancer. The safety profile remained favorable, with 100% median relative dose intensity and no treatment-related discontinuations at the 32 mg dose level.
Down 4.3% since our story on 20 Nov: $14.22 when we broke it → $13.61 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 21 Oct | $14.49 |
|---|---|
| 22 Oct | $14.04 |
| 23 Oct | $14.39 |
| 26 Oct | $14.99 |
| 27 Oct | $15.22 |
| 28 Oct | $15.12 |
| 29 Oct | $14.98 |
| 30 Oct | $14.35 |
| 2 Nov | $14.05 |
| 3 Nov | $14.64 |
| 4 Nov | $14.91 |
| 5 Nov | $13.27 |
| 6 Nov | $14.41 |
| 9 Nov | $15.61 |
| 10 Nov | $15.48 |
| 11 Nov | $16.80 |
| 12 Nov | $15.78 |
| 13 Nov | $15.66 |
| 16 Nov | $15.11 |
| 17 Nov | $13.89 |
| 18 Nov | $13.76 |
| 19 Nov | $14.22 |
| 20 Nov | $13.61 |
Strategic Development Timeline
The clinical data supports a significant shift in Erasca development timeline. The company is now accelerating the initiation of a Phase 3 trial for first-line pancreatic cancer, targeting the first half of 2027. This move leverages the high response rates observed in heavily pre-treated populations to move into earlier treatment lines. Additionally, initial data for ERAS-4001, a pan-KRAS inhibitor, showed encouraging monotherapy activity. Erasca intends to combine ERAS-4001 with ERAS-0015, potentially creating a vertical inhibition strategy to address RAS-mutant solid tumors that currently have limited precision medicine options.
Business Overview
Erasca is a clinical-stage precision oncology company focused on discovering and developing therapies for patients with RAS-mutant cancers. The company mission is to target the RAS-MAPK pathway, which is one of the most frequently mutated pathways in human oncology. Their pipeline includes multiple programs designed to inhibit various nodes of this pathway, including pan-RAS molecular glues and pan-KRAS inhibitors. Headquartered in San Diego, the company utilizes a structure-based drug discovery approach to identify small molecules that can bind to difficult-to-target proteins like KRAS, which was historically considered undruggable by the pharmaceutical industry.
Industry Landscape
The market for RAS-mutant cancer therapies is undergoing rapid evolution as the biotechnology sector moves beyond specific G12C inhibitors toward pan-RAS solutions. Pancreatic cancer remains a particularly challenging indication, with KRAS mutations present in approximately 90% of cases and a five-year survival rate that is among the lowest in oncology. Current standard-of-care treatments for first-line pancreatic cancer typically involve intensive chemotherapy regimens like gemcitabine plus nab-paclitaxel. Erasca pursuit of a molecular glue that targets multiple RAS isoforms could provide a more targeted alternative or a complementary treatment to these traditional cytotoxic therapies.
| Share price | $14.22 |
|---|---|
| Market cap | $5.0B |
| 1-month price change | -2.74% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Erasca, Inc. announcing updated Phase 1 clinical data and an accelerated Phase 3 trial timeline.
Track Erasca, Inc. live
Get the next Erasca, Inc. SEC filing seconds after it lands.